AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of Formula (I)-compounds

in which

the various R1, R2, R3 and R4R1, R2, R3 and R4, which can be the same or different, are H, OH,

OPO3H2 or OCH2OPO3H2 and their disodium salt, OMe, OCH2O, NO2NO2, F, Cl, or Br;

 $-R1-R2--R_1-R_2$ can also be together: $-CR8-CR9-X--CR_8-CR_9-X-$:

-R₁-R₂- can also be together: OCH₂O:

-R₂-R₃- can also be together: OCH₂O;

-R₃-R₄- can also be together: OCH₂O;

Y is a group selected from

w : cis o trans

R5 and R6 R_5 and R_6 , which can be the same or different, are H or halogen;

R7 is H, OMe, SO2Ph;

SIMONI ET AL. Appl. No. 10/563,465 July 28, 2008

Ar is a group selected from:

R8. R9 and R10R8. R9 and R10, which can be the same or different, are H, OH, $\frac{OPO3H2}{OPO_3H_2}$ or $\frac{OCH2OPO3H2}{OCH_2OPO_3H_2}$ and their disodium salt, $\frac{OR11}{OCH_2O}$, $\frac{OCH2O}{OCH_2O}$, $\frac{OCH2O}{OCH2O}$, $\frac{OCH2O}{OCH2O}$, $\frac{OCH2O}{OCH2O}$, $\frac{OCH2O}{OCH2O}$, $\frac{OCH2O}{OC$

R11 is C1-C4 R_{11} is C_1 - C_4 alkyl or acyl, aminoacids residue;

X is O, S, N, NR12 and;

R12 is H, CH3, CH2Ph;

Z is CH. N;

with the proviso that the formula (I) compound is not combretastatin A-1, combretastatin A-2, combretastatin A-4, and their disodium phosphates derivatives and with the exclusion of the following compounds:

2-phenyl-6-trans-styryl-benzo[b]furan;

2,3 diphenyl 6-trans-styryl-benzo[b]furan;

2-phenyl-6-(4-methoxy)-trans-styryl-benzo[b]furan;

2 phenyl 6 (3.4 dimethoxy) trans styryl benzo[b]furan;

2-phenyl 6-(3,4,5-trimethoxy) trans styryl benzo[b]furan;

2 phenyl-6-(3,4-methylenedioxy) trans styryl-benzo[b]furan;

2,3-diphenyl-6 (4-methoxy)-trans-styryl-benzo[b]furan;

2-phenyl-5-trans-styryl-benzo[b]thiophene;

methyl;

```
2 phenyl-5-(4-methoxy) trans-styryl benzo[b]thiophene;
2-phenyl-5-(3,4-methylenedioxy) trans-styryl-benzo[b]thiophene:
2-phenyl-6-trans-styryl-benzo[b]thiophene:
2-phenyl-6-(4-methoxy)-trans-styryl-benzo[b]thiophene;
2-phenyl-6 (4-chloro) trans-styryl-benzo[b]thiophene;
Piceatannol:
1 (3 furanyl) 2 (3,4,5 trimethoxyphenyl)ethene;
1-(3-thiophenyl)-2-(3.4,5-trimethoxyphenyl)ethene;
1-(2-furanyl)-2-(3,4.5-trimethoxyphenyl)ethene;
and with the proviso that
-when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H,
Ar is phenyl, R8 and R9 are hydrogen, R10 is not methoxy;
-when R1 is hydrogen and R2-R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H,
Ar is phenyl. R8 is hydrogen, R9 is 2-chloro, R10 is not 4-methoxy;
when R1 is hydrogen and R2-R4 are trimethoxy, Y is a double bond, R5 and R6 are H, Ar is
phenyl, at least one of R8-R10 is not hydrogen;
when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H,
Ar is phenyl, R8 and R9 are hydrogen, R10 is none of 4 chloro, 4 bromo, 4 nitro, 4 hydroxy, 4
acetyl, 4 ethoxy, 4 C1 C4 alkyl;
```

- when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H,

Ar is phenyl, R8 is hydrogen, R9 is 4-nitro or 4-amino, R10 is none of 3-chloro, 3-methoxy, 3-

- —when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is a *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3 nitro or 3 amino, R10 is none of 3 chloro, 3 methoxy, 3 methyl;
- when R1 is hydrogen and R2-R4 are 2,3,4-trimethoxy, Y is a double bond, R5 and R6 are H,

 Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;
- —when R1 is hydrogen and R2 R4 are 3,4.5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 is hydrogen, R9 is 3 methoxy, R10 is not 5 methoxy;
- —when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R10 are not-methoxy;
- when R1 and R2 are hydrogen and R3 R4 are 3,4 dimethoxy, Y is a double bond, R5 and R6 are H. Ar is phenyl. R8 and R9 are hydrogen, R10 is not 4 methoxy;
- when R1- and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9-R10 are not 3,5-dimethoxy;
- -when R1 and R2 are hydrogen and R3-R4 are 3,4-dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8-R10 is not hydrogen;
- —when R1 and R2 are hydrogen and R3 R4 are 3,5 methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4 methoxy;
- -when R1 and R2 are hydrogen and R3 R4 are 3,5 methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4 acetyl;
- —when R1 is hydrogen and R2—R4 are 3,4,5 trimethoxy; Y is a double bond, R5 and R6 are H;
 Ar is not pyridyl;
- when R1 is hydrogen and R2-R4 are 3,4,5 trimethoxy, Y is *cis* double bond. R5 and R6 are H. Ar is phenyl, R8 is hydrogen, R9 is 3 amino, R10 is 4 NHR11, R11 is not the residue of serine:

-when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy: -when R1 is hydrogen and R2-R4 are 3,4.5-trimethoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not a 4-alkyloxy-group having from 1 to 3 carbon atoms, or a 4 alkyl group having from 1 to 4 carbon atoms, or a halogen atom -when R1 is hydrogen and R2-R3 are 3,4-methylenedioxy, R4 is 5-methoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3 amino, R10 is not 4 methoxy; -when R1 is hydrogen and R2-R4 are 2,3,4 trimethoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3 amino, R10 is not 4 methoxy: -when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of serine, R10 is not 4-methoxy; -when R1 is hydrogen and R2-R3 are 3.4 methylenedioxy, R4 is 4-methoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of the aminoacid cysteine, glycine, phenylalanine, serine, triptophan, tyrosine, valine, R10 is not 4 methoxy; when R1 is hydrogen and R2 R3 are 3,4 methylenedioxy, R4 is 4 methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NO2 or NH2, R10 is not 4-methoxy; when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy. Y is cis double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 -R10 is not hydrogen; -when R1 is hydrogen and R2 R4 are 3.4.5 trimethoxy, Y is a double bond, R5 and R6 are H. Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not-3-fluoro; -when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H₃ Ar is phenyl, R8 is hydrogen, R9 is 4 methyl, R10 is not 3-fluoro or 3-hydroxy;

- —when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4 methoxy, R10 is not 3 methoxy;
- —when R1 is hydrogen and R2 R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is 3-tluoro, R9 is 4-methoxy, R10 is not 2- or 5-fluoro;
- —when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is *eis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4 methoxy. R10 is not 3 hydroxy or 3 amino:
- when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy. Y is cis double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro or 3-bromo;
- -when R1 is hydrogen and R2-R4 are 3,4,5 trimethoxy, Y is eis double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-hydroxy;
- when R1 is hydrogen and R2 R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3 methyl, R10 is not 4 methyl;
- —when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *eis* double bond, R5 and R6 are H, Ar is phenyl. R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-hydroxy;
- -when R1- R2 are hydrogen and R3-R4 are 3,5-dihydroxy, Y is *trans* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3 hydroxy, R10 is not 5 hydroxy;
- when R1-R3 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4 dimethyl, and R4 is not 4 methoxy;
- -when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4 dimethyl, R4 is 4 methoxy, R3 is not 3 fluoro or 3 bromo or 3 nitro or 3 hydroxy;
- -when R1-R2 are hydrogen, Y is a double bond. R5 and R6 are H, Ar is phenyl, R8-R10 are 3,4,5 triethoxy, R4 is 4 methoxy, R3 is not 3-fluoro or 3-chloro or 3-bromo or 3-hydroxy;

when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-hydroxy, R3 is not 3-fluoro or 3-hydroxy;

when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-methoxy, R3 is not 3-fluoro;

when R1-is hydrogen, R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8-R10 is not hydrogen;

when R1 and R2 are hydrogen, R3 is 3-hydroxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8-R10 is not hydrogen;

when R1-is hydrogen, R2-R4 are 3,4,5-trimethoxy,

Y is

Ar is indolyl, wherein at least one of R8 R10 is different from hydrogen; their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

2. (currently amended) Compound according to claim 1, selected from the group consisting of:

2 methoxy 5 [3 methoxy 5 (3,4,5 trimethoxy-phenyl) 4,5 dihydro 4 isoxazolyl] phenol; 2 methoxy 5 [3 methoxy 4 (3,4,5 trimethoxy-phenyl) 4,5 dihydro 5 isoxazolyl] phenol;

```
5-[3-benzenesulphonyl-4-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-4-isoxazolyl] 2-methoxy-
phenol:
5-[3-benzenesulphonyl-5-(3,4,5-trimethoxy-phenyl)-4,5-dihdro-5-isoxazolyl]-2-methoxy-
phenol:
2 methoxy 5 [3 (3,4,5 trimethoxy phenyl) 4,5 dihydro 5 isoxazolyl] phenol:
2 methoxy 5 [5-(3,4,5 trimethoxy phenyl) 4,5 dihydro 3-isoxazolyl] phenol;
2-methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-3-isoxazole]-phenol;
cis-6 [2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;
trans 6-[2 (3,4,5 trimethoxy phenyl) vinyl] benzo[b]thiophen 4-ol;
cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophene;
trans 4 methoxy 6 [2 (3,4,5 trimethoxy-phenyl)-vinyl] benzo[b]thiophene;
cis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;
trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;
cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;
trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;
cis-5-[2-(3,4.5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-7-ol;
trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl] benzo[b]thiophen-7-ol;
cis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol;
trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol;
cis 1-methoxy-3-[2-(3.4,5-trimethoxy-phenyl)-vinyl]-naphthalene;
methoxy-3-[2-(3.4,5-trimethoxy-phenyl)-vinyl] naphthalene;
cis 7 methoxy 1 methyl-5 [2 (3,4.5 trimethoxy-phenyl) vinyl]-1H indazole;
trans-7-methoxy-1-methyl-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-1H-indazole;
```

```
2 nitro 5 [2-(3,4,5 trimethoxy phenyl) vinyl] thiophene;
2 nitro-5-[2-(3,4,5-trimethoxy phenyl) vinyl]-furan;
cis 3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;
trans-3-[2-(3,4.5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;
disodium 6[(Z) 2-(3,4,5 trimethoxy phenyl)ethenyl] 1 benzo thiophen 4 of 4 O phosphate;
disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-phosphate;
6-[(Z) 2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;
6-[(E)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;
6-[(Z)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;
6-[(E)-2-(3-methoxy-4,5-methylenedioxyphenyl-1-yl)-vinyl]-1-benzofuran-4-ol;
disodium 6 [(Z) 2 (3,4,5 trimethoxy phenyl)ethenyl] 1 benzo thiophen 4 of 4 O
methyloxyphosphate;
disodium 6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-
methyloxyphosphate;
6-[(Z)-2 (7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;
6 [(E) 2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol
6-[(Z)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;
6-[(E)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;
disodium 6[(Z) 2 (3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol-4-O-
methyloxyphosphate:
disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-
methyloxyphosphate;
6 [(Z) 2 (7-methoxy-1,3-benzodioxol-5-yl)vinyl] 1-benzothiophene-4-ol;
```

SIMONI ET AL. Appl. No. 10/563;465 July 28, 2008

cis-2 Methoxy-5 [2 (4 methoxy benzofuran-6 yl) vinyl] phenol;
cis-2 Methoxy-5 [2 (7 methoxy benzofuran-5 yl) vinyl] phenol;
cis-2 Methoxy-5 [2 (4 methoxy benzo[b]thiophen-6 yl) vinyl] phenol;
cis-6 [2 (3,5 dimethoxy-phenyl) vinyl] benzo[b]thiophen-4 ol;
cis-5-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-7-ol; and
cis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-4-ol;
their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

- 3.-4. (canceled).
- 5. (withdrawn/currently amended) Use according to claim-3 for the preparation of a medicament for the treatment of A method of treating cancers that respond to cytotoxic activity comprising administering to a subject in need of same an effective amount of a compound of claim 1.
- 6. (withdrawn/currently amended) [[Use]] The method according to claim 5, in which said cancer is selected from the group consisting of sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, lymphoid leukaemia, myeloid leukaemia, monocytic leukaemia, megakaryocytic leukaemia, [[or]] and Hodgkin's disease.
- 7. (withdrawn/currently amended) Use of compounds according to claim 1 for the preparation of a medicament for the treatment of A method of treating diseases related to

SIMONI ET AL. Appl. No. 10/563,465 July 28, 2008

abnormal angiogenesis comprising administering to a subject in need of same an effective amount of a compound of claim 1.

- 8. (withdrawn/currently amended) [[Use]]The method according to claim 7, in which said disease is selected from the group consisting of arthritic disease, tumours responding to antiangiogenic activity, metastatic spread, diabetic retinopathy, psoriasis, chronic inflammation, and atherosclerosis.
- 9. (withdrawn/currently amended) [[Use]] The method according to claim [[4]]5, in which, in the treatment of tumours, said medicament compound is combined with at least one other antiblastic drug.
- 10. (withdrawn/currently amended) [{Use}]The method according to claim 9, in which said antiblastic drug is selected from the group consisting of alkylating agents; topoisomerase inhibitors; antitubulin agents; intercalating agents; antimetabolites; naturally occurring products such as Vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxanes and anticancer vaccines.
- 11. (previously presented) Pharmaceutical A pharmaceutical composition containing as the active ingredient a compound according to claim 1 in a mixture with a pharmaceutically acceptable excipient or diluent.
 - 12. (withdrawn) Use of the compound with the formula

SIMONI ET AL. Appl. No. 10/563;465 July 28, 2008

in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claim 1.

13. (withdrawn) Compound with the formula:

in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

14. (withdrawn) Compound with the formula

in which

 $X \ is \ oxygen \ or \ sulphur, \ R \ is \ methyl, \ or \ terbutyl-dimethylsilyl.$

R1 is formyl.

15. (withdrawn) Use of the compound with the formula

SIMONI ET AL. Appl. No. 10/563,465 July 28, 2008

in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claim 1.

16. (withdrawn) Compound with the formula

in which

X is oxygen or sulphur.

17. (withdrawn) Compound with the formula

in which

X is oxygen or sulphur.

18. (canceled).